MARKET

TTIPF

TTIPF

Thiogenesis
OTCQX
0.585
NaN%
Closed 09:30 12/04 EST
OPEN
--
PREV CLOSE
0.585
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.586
52 WEEK LOW
0.415
MARKET CAP
26.92M
P/E (TTM)
-7.2133
1D
5D
1M
3M
1Y
5Y
1D
Thiogenesis Therapeutics Announces Phase 3 Trial Plans for TTI-0102 in Nephropathic Cystinosis
Reuters · 11/24 14:01
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
Newsfile · 11/24 14:00
Thiogenesis Therapeutics Reports Positive Phase 2 Results for MELAS and Advances Pipeline for Leigh Syndrome and Cystinosis
Reuters · 11/04 14:02
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
Newsfile · 11/04 14:00
Thiogenesis Announces Extension to Investor Relations Agreement
Newsfile · 10/03 20:00
Weekly Report: what happened at TTIPF last week (0908-0912)?
Weekly Report · 09/15 12:27
Thiogenesis Therapeutics Corp. Held Annual General Meeting of Shareholders
Reuters · 09/11 13:01
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update
Newsfile · 09/11 13:00
More
About TTIPF
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Webull offers Thiogenesis Therapeutics Corp stock information, including OTCQX: TTIPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTIPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TTIPF stock methods without spending real money on the virtual paper trading platform.